Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on developing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced it will release its fourth quarter and full year 2024 financial results before market open on Tuesday, March 4, 2025.
The company will host a conference call and webcast to discuss the results on March 4, 2025, at 8:00 a.m. ET. Interested parties can register for the live conference call, and a webcast will be available on the company's Investor Relations website, remaining accessible for at least 30 days afterward.
Y-mAbs Therapeutics (Nasdaq: YMAB), una azienda biofarmaceutica in fase commerciale focalizzata nello sviluppo di nuovi prodotti terapeutici basati su radioimmunoterapia e anticorpi per il trattamento del cancro, ha annunciato che pubblicherà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 prima dell'apertura del mercato martedì 4 marzo 2025.
L'azienda organizzerà una conferenza telefonica e un webcast per discutere i risultati il 4 marzo 2025, alle 8:00 a.m. ET. Le parti interessate possono registrarsi per la conferenza telefonica in diretta, e un webcast sarà disponibile sul sito web delle Relazioni con gli Investitori dell'azienda, rimanendo accessibile per almeno 30 giorni dopo.
Y-mAbs Therapeutics (Nasdaq: YMAB), una empresa biofarmacéutica en etapa comercial centrada en el desarrollo de nuevos productos terapéuticos basados en radioinmunoterapia y anticuerpos para el tratamiento del cáncer, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 antes de la apertura del mercado el martes 4 de marzo de 2025.
La empresa llevará a cabo una conferencia telefónica y un webcast para discutir los resultados el 4 de marzo de 2025, a las 8:00 a.m. ET. Las partes interesadas pueden registrarse para la conferencia telefónica en vivo, y un webcast estará disponible en el sitio web de Relaciones con Inversores de la empresa, permaneciendo accesible durante al menos 30 días después.
Y-mAbs Therapeutics (Nasdaq: YMAB), 상업 단계의 생물 제약 회사로서 암 치료를 위한 새로운 방사면역요법 및 항체 기반 치료 제품 개발에 중점을 두고 있는 회사는 2024년 4분기 및 전체 연도 재무 결과를 2025년 3월 4일 화요일 시장 개장 전에 발표할 것이라고 밝혔습니다.
회사는 2025년 3월 4일 오전 8시(동부 표준시)에 결과를 논의하기 위한 전화 회의 및 웹캐스트를 개최할 예정입니다. 관심 있는 당사자는 라이브 전화 회의에 등록할 수 있으며, 웹캐스트는 회사의 투자자 관계 웹사이트에서 제공되며, 이후 최소 30일 동안 접근할 수 있습니다.
Y-mAbs Therapeutics (Nasdaq: YMAB), une entreprise biopharmaceutique en phase commerciale axée sur le développement de nouveaux produits thérapeutiques basés sur la radio-immunothérapie et les anticorps pour le traitement du cancer, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 avant l'ouverture du marché le mardi 4 mars 2025.
L'entreprise organisera une conférence téléphonique et un webcast pour discuter des résultats le 4 mars 2025 à 8h00 ET. Les parties intéressées peuvent s'inscrire à la conférence téléphonique en direct, et un webcast sera disponible sur le site Web des Relations Investisseurs de l'entreprise, restant accessible pendant au moins 30 jours par la suite.
Y-mAbs Therapeutics (Nasdaq: YMAB), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Entwicklung neuartiger Radioimmuntherapien und antikörperbasierter therapeutischer Produkte zur Krebsbehandlung konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 vor der Markteröffnung am Dienstag, den 4. März 2025, veröffentlichen wird.
Das Unternehmen wird am 4. März 2025 um 8:00 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten, um die Ergebnisse zu besprechen. Interessierte Parteien können sich für die Live-Telefonkonferenz anmelden, und ein Webcast wird auf der Investor Relations-Website des Unternehmens verfügbar sein und mindestens 30 Tage lang zugänglich bleiben.
- None.
- None.
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the fourth quarter and full year 2024 before the market open on Tuesday, March 4, 2025.
Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, March 4, 2025 at 8:00 a.m. ET. To participate in the live conference call, register here. A live audio webcast of the call will be available on the Investor Relations section of the Company’s website at https://ir.ymabs.com/events-and-presentations/events. The webcast will be archived for at least 30 days.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company’s business is subject to risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company’s Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
SADA®, SADA PRIT™, DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
FAQ
When will Y-mAbs (YMAB) release Q4 and full year 2024 earnings?
How can investors join Y-mAbs (YMAB) Q4 2024 earnings call?
Where can I find the replay of Y-mAbs (YMAB) Q4 2024 earnings webcast?
What time is Y-mAbs (YMAB) Q4 2024 earnings conference call?
